Gilead to begin human trials for the inhaled version of coro
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
Gilead Sciences will begin human trials for an inhaled version of its antiviral drug remdesivir in August, the biotech company said 22nd June 2020.

• The company told investors in April that it was looking to develop easier-to-administer versions of the drug, including an inhaled version.

• The drug can’t be administered in pill form because its chemical makeup would impact the liver, the company noted.

• Gilead said it will administer the drug through a nebulizer, a delivery device that can turn liquid medicines into mist.

• Gilead will screen healthy volunteers for the early-stage trial and hope to begin studies in patients with Covid-19 in August.

• It is also exploring whether it can improve patient outcomes by combining remdesivir with other therapies.

• The company has said it can produce “several million” rounds of its antiviral drug next year to help patients fight the coronavirus.

• Remdesivir is considered to be at the forefront in the fight against the novel coronavirus after the drug helped shorten hospital recovery times in a clinical trial.

Source: https://www.cnbc.com/2020/06/22/coronavirus-drug-gilead-to-begin-trials-for-the-inhaled-version-of-remdesivir.html
Dr. j●●●i b●●●●●n and 6 others like this3 shares
Like
Comment
Share